Have a feature idea you'd love to see implemented?
Let us know!
CABA Cabaletta Bio Inc
Price (delayed)
$4.03
Market cap
$196.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.91
Enterprise value
$25.65M
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative,
Highlights
CABA's debt has surged by 76% year-on-year but it is down by 9% since the previous quarter
The equity has grown by 15% YoY but it has contracted by 10% from the previous quarter
CABA's net income has dropped by 57% year-on-year and by 17% since the previous quarter
Cabaletta Bio's quick ratio has decreased by 45% YoY and by 9% QoQ
Key stats
What are the main financial stats of CABA
Market
Valuations
Earnings
Shares outstanding
48.85M
Market cap
$196.86M
Enterprise value
$25.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.98
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$89.98M
EBITDA
-$84.13M
Free cash flow
-$75.66M
Per share
Balance sheet
Liquidity
EPS
-$1.91
Free cash flow per share
-$1.57
Book value per share
$4.13
Revenue per share
$0
TBVPS
$4.5
Total assets
$217.42M
Total liabilities
$17.9M
Debt
$7.4M
Equity
$199.52M
Working capital
$188.36M
Debt to equity
0.04
Current ratio
11.52
Quick ratio
11.35
Net debt/EBITDA
2.04
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.7%
Return on equity
-44%
Return on invested capital
-195%
Return on capital employed
-45.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CABA stock price
How has the Cabaletta Bio stock price performed over time
Intraday
-6.06%
1 week
-13.52%
1 month
-7.78%
1 year
-67.02%
YTD
-82.25%
QTD
-14.62%
Financial performance
How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$100.12M
Net income
-$89.98M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 64% YoY and by 17% from the previous quarter
CABA's net income has dropped by 57% year-on-year and by 17% since the previous quarter
Growth
What is Cabaletta Bio's growth rate over time
Valuation
What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
0.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is down by 11% QoQ and by 10% YoY
CABA's price to book (P/B) is 69% lower than its last 4 quarters average of 3.4 and 53% lower than its 5-year quarterly average of 2.2
The equity has grown by 15% YoY but it has contracted by 10% from the previous quarter
Efficiency
How efficient is Cabaletta Bio business performance
The ROIC has contracted by 32% from the previous quarter but it has grown by 4.2% YoY
Cabaletta Bio's ROE has decreased by 13% from the previous quarter but it has increased by 13% YoY
Cabaletta Bio's return on assets has decreased by 13% QoQ but it has increased by 12% YoY
Dividends
What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CABA.
Financial health
How did Cabaletta Bio financials performed over time
Cabaletta Bio's total liabilities has soared by 71% YoY but it has decreased by 4.5% from the previous quarter
Cabaletta Bio's quick ratio has decreased by 45% YoY and by 9% QoQ
CABA's debt is 96% smaller than its equity
Cabaletta Bio's debt to equity has soared by 100% YoY
CABA's debt has surged by 76% year-on-year but it is down by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.